In an in-vivo study using transgenic murine models with CD34+ and c-kit cells, potent PORCN inhibitor WNT974 in combination with nilotinib was efficacious in reducing neutrophils, white blood cells and myeloid cells in PB, with eradication of CML stem cells and other progenitors in the BM and spleen [18,178,179]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.